Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Aboud, M.; Kaplan, R.; Lombaard, J.; Zhang, F.; Hidalgo, J.; Mamedova, E.; Losso, M.; Chetchotisakd, P.; Brites, C.; Sievers, J.; Brown, D.; Hopking, J.; Underwood, M.; Nascimento, M.; Gartland, M.; Smith, K.; Steinhart, C.; Gatell, J.
• Is Part Of: Journal of infection and public health. Volume 12:Issue 1(2019)
• Page Start: 107
• Publication Date: 2019-01
• Subjects: Communicable diseases -- Periodicals; Public health -- Periodicals; Epidemiology -- Periodicals; Nosocomial infections -- Prevention -- Periodicals; Medical microbiology -- Periodicals; 614.4
• DOI: 10.1016/j.jiph.2018.10.135
• Languages: English
• ISSNs: 1876-0341